Atossa Therapeutics ATOS
Atossa Therapeutics reported a net loss of $5.64 million for Q3 2026.
Atossa Therapeutics (ATOS) filed a 10-Q with the SEC on Nov 10, 2026, 8:00 am ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001193125-26-454468
- Net loss: $5.64 million for the three months ended Sep 30, 2026
- Diluted EPS: -$0.56 for the three months ended Sep 30, 2026
- Cash and equivalents: $20.57 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
Going-concern warning repeated
“These conditions raise substantial doubt as to the Company's ability to continue as a going concern.”
Also in the prior 10-Q (filed Aug 7, 2026). Prior report Prior on EDGAR
Quoted from the filing.
What changed since last quarter
2 new risk factors · 6 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$5.9M | −$8.69M | +32% |
| Net income | −$5.64M | −$8.49M | +34% |
| Operating cash flow | −$5.52M | −$9.64M | +43% |
| Cash | $20.57M | $26.09M | −21% |
New risk factors (2)
- • Holders of our Stapled CVRs may never receive any payment on the Stapled CVRs, and the Stapled CVRs may expire valueless.
- We have never declared or paid cash dividends on our capital stock . In October 2026, our Board of Directors declared a dividend of one Stapled CVR for each outstanding share of our common stock. However, the Stapled CVRs represent only a contingent right to a portion of the net proceeds, if any, from the… +2 more paragraphs
Removed risk factors (6)
- • The ownership of our common stock may become concentrated among a small number of stockholders.
- • The requirements of being a public company may strain our resources, result in litigation, and divert management's attention.
- In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information included in this Quarterly
- AI-enabled tools in the discovery or development of product candidates, or lack of public acceptance of such products, could adversely affect our business, reputation and financial results.
- For more information regarding our legal proceedings refer to Note 12 "Commitments and Contingencies" to the Condensed Consolidated Financial Statements.
- and 1 more in the filing